FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC  

  RSS

Daniel
(@daniel)
New Member Admin
Joined: 3 years  ago
Posts: 212
05/11/2018 1:04 pm  

FDA granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. More Information.  November 2, 2018


ReplyQuote
Share: